Glaukos: Micro-Implants Instead of Eye Drops

Glaukos primarily earns its money from surgical single-use implants for micro-invasive glaucoma procedures, generating recurring revenues with each treated patient. With the independent active ingredient depot iDose TR , the company addresses the problem of insufficient patient adherence to eye drops and thus opens up a significantly larger market beyond mere cataract combination procedures. The demographic aging and the planned expansion into the retina sector offer enormous scaling potential for the company. The US medical technology...